Vai alla homepage

I migliori medici di Infusioni di vitamine a Istanbul - TOP-7 medici

Il contenuto è conforme alla Politica editoriale di Bookimed ed è revisionato da medici

Fahad Mawlood

Nur Afsar

  • 4.7 Eccellente 114 recensioni
  • 7 anni di esperienza
  • Turchia, Istanbul, Quartz Hospital
  • La Dott.ssa Nur Afsar combina oltre 7 anni di esperienza nelle estetiche mediche con un focus su infusioni di vitamine personalizzate presso l'Ospedale Quartz.

    • Specializzata nel ringiovanimento della pelle basato su evidenze e nella mesoterapia
    • Formata in tecniche avanzate come l'Ultherapy e il Radiesse
    • Fluente nelle tecnologie e tendenze estetiche attuali
    • Ha completato una formazione specialistica nelle pratiche di estetica medica
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Esra Ozbasli

  • 5 Eccellente 3 recensioni
  • 23 anni di esperienza
  • Turchia, Istanbul, Assoc. Prof. Dr. Esra Özbaşlı OBGYN & Genital Aesthetics
  • Il Dr. Ozbasli è un ginecologo certificato con oltre 21 anni di esperienza, specializzato in salute femminile e procedure estetiche.

    • Professore associato formato presso la Facoltà di Medicina Cerrahpaşa dell'Università di Istanbul
    • Certificato in Estetica Genitale e Ginecologia Cosmetica
    • Formazione in chirurgia robotica con il Sistema da Vinci
    • Ha completato un'osservazione presso la New York University
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Veysel Ozcan

  • Nuova
  • 14 anni di esperienza
  • Turchia, Istanbul, Veysel OZCAN Clinic
  • 12 anni di esperienza in medicina estetica con formazione specializzata nelle tecniche di infusione di vitamine. Il Dr. Ozcan dà priorità alla soddisfazione del paziente e ai trattamenti innovativi.

    • Certificato dal Ministero della Salute turco in Mesoterapia e Ozonoterapia
    • Ex primario con ruoli di leadership nella sicurezza e qualità ospedaliera
    • Fluente in inglese e curdo per una migliore comunicazione con i pazienti
  • Mostra di più
Infusioni di vitamine
$200 - $250
Informazioni

Nazan Taslidere

  • 5 Eccellente 53 recensioni
  • 31 anni di esperienza
  • Turchia, Istanbul, Istanbul Florence Nightingale Hospital
  • Published journal articles indexed by SCI, SSCI, and AHCI I. Investigation of the effectiveness of teledermatology in the diagnosis of skin lesions in pediatric patients TaslidereN.,KucukO.S. Revista daAssociacaoMedicaBrasileira (1992),vol.69,no.10,2023 (SCI-Expanded) I . Can a Correct Diagnosis Be Established Using the TeledermatologyMethod? TAŞLIDEREN.,SUKÜÇÜKÖ. ACTADERMATOVENEROLOGICACROATICA,vol.30,no.1,pp.32-39,2022 (SCI-Expanded) I I. Melkersson-Rosenthal syndrome induced by COVID-19: A case report TaşlıdereB.,MehmetajL.,ÖzcanA.B.,GülenB.,TaşlıdereN. AmericanJournalofEmergencyMedicine,vol.41,2021 (SCI-Expanded) IV. Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them? CENGİZ F.P.,EMİROĞLUN.,BAHALIA.G.,DİZMAND.,TAŞLIDEREN.,AkarslanT.C.,GunesB.,MERTÖ.,KÜÇÜKÖ.S., ONSUNN. DERMATOLOGICTHERAPY,vol.33,no.4,2020 (SCI-Expanded)

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Dr Makbule Dundar

  • 5 Eccellente 3 recensioni
  • 27 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Makbule DÜNDAR, M.D.

    Dermatology

    Areas of Expertise and Interest

    • General Dermatology
    • Venereal Diseases
    • Cosmetic Dermatology
    • Laser Treatments
    • Dermoscopy
    • Non-surgical Aesthetic Procedures (Peeling, Fillers, Botulinum Toxin, etc.)

    Education and Career

    • 1989 – 1995 Istanbul University, Istanbul Faculty of Medicine – M.D. Degree
    • 1996 – 1999 Haseki State Hospital – Dermatology Residency Training
    • 1999 – 2003 Fizikom Aesthetic and Laser Center – Specialist in Dermatology
    • 2003 – 2006 TBV Hizmet Hospital – Specialist in Dermatology
    • 2006 – 2008 Medical Park Bahçelievler Hospital – Specialist in Dermatology
    • 2008 – 2014 Private Istanbul Medipol Hospital – Specialist in Dermatology
    • 2014 – 2017 Memorial Wellness – Specialist in Dermatology
    • 2017 – 2024 Saltat Clinic, Göztepe Branch – Specialist in Dermatology
    • 2024 – Present Medipol Acıbadem District Hospital – Specialist in Dermatology, Head of Aesthetic Medicine Department

    Career

    Born in 1960 in Turkey, Dr. Makbule Dündar graduated from Istanbul University Faculty of Medicine in 1995 and completed her residency in Dermatology at Haseki State Hospital in 1999. Throughout her career spanning over two decades, she has worked in prestigious institutions and clinics, focusing on both clinical dermatology and aesthetic procedures. Her interests include laser therapies, dermoscopy, and minimally invasive cosmetic applications. She has participated in numerous international congresses, workshops, and hands-on trainings.

    She currently serves as the Responsible Physician of the Aesthetic Medicine Department at Medipol Acıbadem District Hospital, where she combines her medical expertise with cosmetic dermatology practice.

    Publications

    • Congenital Cutis Marmorata Telangiectatica: A Case Report – Çiftçi M., Erdoğan F., Dündar M. – Haydarpaşa Numune Medical Journal, 2012
    • A Case of Lichen Planus Pemphigoides – Dündar M., Derviş E., et al. – Turkiye Klinikleri Dermatology, 2000
    • The Role of Dermoscopy in Diagnosing Pigmented Lesions – Derviş E., Dündar M., et al. – Haseki Medical Bulletin, 2000
    • The Importance of Dermoscopy in Pigmented LesionsSpecialization Thesis, 1999

    Certifications and Awards

    • Numerous practical training programs in botulinum toxin, dermal fillers, peeling, and aesthetic lasers
    • Participation in multiple national and international dermatology congresses and workshops
    • Recipient of various hands-on training certificates in aesthetic dermatology, dermatosurgery, and team management in healthcare

    Professional Affiliations and Memberships

    • Istanbul Medical Chamber
    • Turkish Society for Dermatology and Venereology
    • Turkish Dermatology Association
    • European Academy of Dermatology and Venereology (EADV)
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Nail Paksoy

  • 4.5 Buono 2 recensioni
  • 15 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Esin Ozlem Atmis

  • 4.9 Eccellente 47 recensioni
  • 12 anni di esperienza
  • Turchia, Istanbul, Health Point World Clinic
  • La Dott.ssa Atmis porta nel suo studio presso Health Point World Clinic una formazione internazionale dall’Italia e dagli Stati Uniti.

    • Specializzata in otorinolaringoiatria e chirurgia della testa e del collo
    • Formata presso istituzioni prestigiose tra cui l'Università di Palermo
    • Ha lavorato presso l'Ospedale Acibadem – uno dei principali fornitori di servizi sanitari in Turchia
    • Fluente in inglese e italiano per i pazienti internazionali
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Come scegliere il medico e la clinica giusti: consigli degli esperti

Quando scegli un medico o una clinica, tieni presente questi punti chiave:
Controlla le credenziali
Verifica le certificazioni di enti come ISAPS, JCI o degli ordini medici pertinenti.
Verifica i tassi di successo
Scegli medici con grande esperienza e comprovata competenza nel trattamento specifico.
Leggi le recensioni dei pazienti
Recensioni reali dei pazienti Bookimed per conoscere la loro esperienza.
Assicura una comunicazione efficace
Scegli cliniche che offrono servizio di traduzione per facilitare il trattamento.
Chiedi informazioni sui servizi
Conferma se il prezzo include servizi come alloggio, trasferimenti locali e assistenza post-trattamento per evitare costi nascosti.
Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.
Yan Matsiivskiy
Capo del team dei coordinatori medici

Bookimed Insights: Principali specialisti in Infusioni di vitamine in Turchia (2026)

Bookimed ha coordinato 4 richieste per Infusioni di vitamine in Turchia, collaborando con 7 specialisti di alto livello. I medici in questa tabella sono selezionati in base alle loro credenziali internazionali, esperienza clinica e risultati dei pazienti. La classifica del 2026 è composta da dati verificati su casi reali e dai programmi attuali delle nostre cliniche partner.
MedicoesperienzaBuona scelta perCosa li distingueClinica e posizioneConsulto
7 anni di esperienzaInfusioni di benessere personalizzateSi concentra sul benessere olistico attraverso terapie vitaminiche personalizzate. Formato presso la Merz Academy e la Ulthera Academy per tecniche estetiche avanzate.
Turchia
Prezzo su richiesta
23 anni di esperienzaSalute e bisogni estetici delle donneSpecializzata in procedure estetiche e cosmetiche genitali con certificazioni in ringiovanimento vaginale e chirurgia robotica. Formata presso prestigiose istituzioni in Turchia e negli Stati Uniti.
Turchia
Prezzo su richiesta
14 anni di esperienzaTerapie di infusione vitaminica personalizzateSpecializzato in trattamenti integrativi come la Mesoterapia e l'Ozonoterapia. Ex primario con leadership nella qualità e sicurezza del paziente.
Turchia
Prezzo su richiesta
12 anni di esperienzaTerapia di infusione vitaminicaLa formazione medica internazionale migliora il suo approccio ai trattamenti per il benessere. Attualmente esercita presso l'ospedale Fulya Acibadem a Istanbul.
Turchia
Prezzo su richiesta